LT 4012
Alternative Names: LT-4012Latest Information Update: 25 Apr 2024
At a glance
- Originator LTT Bio-Pharma
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 05 Apr 2024 LT 4012 is available for licensing as of 05 Apr 2024. https://www.ltt.co.jp/en/partnership/licensing/licenceout/ (LTT Bio-Pharma website, April 2024)
- 05 Apr 2024 Phase-I clinical trials in COVID-2019 infections (unspecified route) prior to April 2024 (LTT Bio-Pharma pipeline, April 2024)
- 05 Apr 2024 Preclinical trials in COVID-2019 infections in Japan (unspecified route) prior to April 2024 (LTT Bio-Pharma website, April 2024)